Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 61INDUSTRY 41NETWORK 3UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

Tamoxifen 10Docetaxel 8Trastuzumab 7Paclitaxel 6Letrozole 6Gemcitabine 6Exercise 6Control Groups 6exemestane 5Indocyanine Green 5Cyclophosphamide 5Carboplatin 5Anastrozole 5pertuzumab 4dalpiciclib 4Vinorelbine 4Doxorubicin 4Capecitabine 4pyrotinib 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Fulvestrant 3Cisplatin 3ferumoxides 2Zoledronic Acid 2Tablets 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Neoplasms × Everolimus × Clear all
NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

National Cancer Center, Korea

Phase 1/2 Terminated
23 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡